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Abstract 
We described the health resource utilisation (HRU) and associated direct medical 
costs of managing epilepsy in children and young people (CYP) using population-
level data from the United Kingdom.  
The study cohort were CYP born between 1988 and 2004 who were newly 
diagnosed with epilepsy and identified using a nationally representative primary care 
database from the United Kingdom. Reference unit costs were applied to each 
element of HRU to calculate annual direct medical costs per child. We assessed 
whether HRU and costs differed by time from diagnosis, age, sex and socioeconomic 
deprivation. 
Of 798 CYP newly diagnosed with epilepsy, 56% were male and the mean age at 
diagnosis was 5.6 years. The highest burden of HRU was in the first year following 
diagnosis with a mean annual cost of £930 (95% confidence interval (CI) £839-
1,022) per child in this first year. This decreased to £461 (95%CI 368-551) in the 
second year which remained fairly constant each subsequent year (£413 (95% CI 
282-540) in the 8th year). The highest contribution to the annual medical costs was 
from inpatient hospital admissions followed by the costs of AEDs. Mean annual 
medical costs were significantly higher in children under 6 years of age compared 
with older children (p<0.01), but were similar across socioeconomic groups 
(p=0.62). 
The direct medical costs of HRU in CYP with epilepsy are higher in the first year 
after diagnosis compared to subsequent years, reflecting HRU related to the 
diagnostic process in the first year. Medical costs did not vary substantially by sex or 
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socioeconomic deprivation indicating a similar level of consultation and care across 
these groups.  
Keywords: Epilepsy in children, general practice, medical cost, health resource  
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1. Introduction 
Epilepsy is a serious chronic neurological disorder that has a higher incidence (70-
116 per 100,000 person-years) in children and young people (CYP), under 18 years, 
than in adults (30-55 per 100,000 person-years) (Forsgren et al., 2005; Kotsopoulos 
et al., 2002; Meeraus et al., 2013). As many clinical subtypes of childhood epilepsy 
persist into adulthood (Guerrini 2006), epilepsy has long term clinical care 
requirements and a high economic burden at individual, family, health service and 
societal levels in the United Kingdom (UK) and in Europe (Pugliatti et al., 2007). 
The total direct medical cost of epilepsy to the United Kingdom (UK) National 
Health Service (NHS) was estimated to be £170 million in 1994 when the population 
was 59.8 million people (Cockerell et al., 1994). This included antiepileptic drug 
(AED) treatment, outpatient attendances, inpatient hospital admissions, diagnostic 
imaging, blood chemistry tests, general practitioner and specialist consultations. This 
estimate was based on aggregated data of 1628 adults and children with epilepsy.  In 
2005, Beghi et al reviewed published studies on the cost of childhood epilepsy and 
concluded that there was very limited knowledge of the economic impact of epilepsy 
in CYP due to the scarcity, inconsistency and poor comparability of published 
articles (Beghi et al., 2005) and no subsequent studies have estimated these costs at a 
population level in the UK.  
Nevertheless, there are appear to be wide differences in incidence, prognosis and 
management between adults and CYP with epilepsy (Beghi et al., 2005). Studies of 
health resource utilisation (HRU) in regions of Canada and Wales have indicated that 
CYP under 18 years of age are more likely than adults to see neurologists, visit 
emergency departments, and have more inpatient and outpatient hospital admissions 
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(Jette et al., 2008; Morgan et al., 2000). Studies in these populations, consisting 
mainly of adults, also showed HRU differences by sociodemographic factors, such 
as increased hospital care utilisation for epilepsy in those with higher socioeconomic 
deprivation in Wales (Jette et al., 2008; Morgan et al., 2000). These studies, 
however, did not assess relationships specifically in CYP nor did they estimate any 
associated costs, which are required to inform service configuration and evaluation 
for CYP.  Updated HRU and cost data should help service planning and provision by 
understanding whether there are areas where cost budgets need to be rebalanced 
between epilepsy diagnosis, treatment and acute management and services. In 
addition, identifying whether and how epilepsy HRU and costs differ across 
sociodemographic groups is crucial for planning area-level population service 
provisions and modifications.  
Epilepsy in the UK is managed principally via primary care in collaboration with 
secondary care settings (Stokes et al., 2004). The aim of our study was to use a large 
population-based general practice database to estimate patient-level direct medical 
costs of managing epilepsy in CYP. We also assessed whether HRU and direct 
medical costs varied by age, sex, socioeconomic status and the time from diagnosis 
of epilepsy.  
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2. Methods 
2.1. Data Source  
Data were extracted from The Health Improvement Network (THIN), a 
computerised primary care database that contained longitudinal electronic medical 
records from 255 general practices across the UK at the time data were extracted. In 
2004, THIN had approximately 3.2 million patients which, covered 5.3% of the UK 
population (THIN, 2012). Data in THIN include anonymised patient records with 
demographic information, medical diagnoses (including those resulting from 
referrals to specialists), prescriptions, laboratory results, records of hospital 
admissions and medical measurements. Diagnoses and investigations are recorded 
using Read codes which have a hierarchical structure and include comprehensive 
clinical terminology (Stuart-Buttle et al., 1996).   
2.2. Study population 
From an initial population of all CYP born between January 1st , 1988 and  
November 30th , 2004, we identified all CYP (up to age 16 years) with newly 
diagnosed epilepsy. We defined CYP as having epilepsy if they had at least one 
diagnostic Read code for epilepsy, selected according to consistency with the 1989 
International League Against Epilepsy (ILAE 1989) and section G40 of the 
International Statistical Classification of Diseases, 10th Revision, and at least one 
prescription for an AED shown in Table 1. To avoid misdiagnosis of epilepsy, We 
excluded codes of disorders that mimic epilepsy such as febrile convulsions and we 
also excluded antiepileptic drugs prescribed for diseases other than epilepsy  (Ali 
2012). Our code lists were constructed with consultation from a Clinical Associate 
Professor of Paediatric Neurology in the Division of  Child Health, the University of 
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Nottingham’s Queen Medical Centre.  In addition, to be considered as incident cases 
their first epilepsy diagnosis and any related treatment had to occur at least 6 months 
after their date of registration with the general practice to be considered as newly 
diagnosed, unless they had been registered within the first 6 months of life (70% of 
the population were registered within 6 months of birth). We also included only CYP 
who had at least one year of registered follow-up data and CYP were followed up to 
8 years after their initial diagnosis of epilepsy or, if earlier, to their date of death, the 
date when they transferred out of the general practice or the last date of data 
collection on November 30th, 2004. We extracted information from the CYP’s 
records on their age, sex, and socioeconomic deprivation. Age was calculated at the 
beginning of each year as a time-varying variable and categorised into four groups (< 
2, 2-6, 7-12 and > 12 years) based on the British National Formulary (BNF 2011) 
age-specific dosage indications for CYP with epilepsy. The Townsend index, in 
quintiles, which is an area-based measure derived from 2001 census data linked to 
patients’ post codes, was used as a measure of household-level socioeconomic 
deprivation (Jordan et al., 2004). Some cases were diagnosed to have benign 
epilepsy syndromes who were occasionally prescribed anticonvulsant medication in 
their therapeutic files. Therefore, all health resources they consumed were included 
in the calculation of the cost of epilepsy.  
2.3. Information on heath resource use 
The following elements of HRU were extracted from all patients’ records: 
General practice (GP) consultations: The number of consultations on unique days 
Outpatient hospital care: Read codes for outpatient attendances including referrals 
to paediatric neurology were extracted from the medical files. Specific recording of 
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paediatric neurology attendances, however, were only found for 3% of the study 
population, suggesting that they were systematically under-recorded or lacked 
specificity in coding of these attendances. The 2004 NICE guideline for diagnosis 
and management of epilepsy (Stokes et al., 2004) recommended that the diagnosis of 
epilepsy is established by a neurologist or a paediatric specialist in epilepsy. 
Therefore, we included one paediatric neurologist appointment per CYP in the first 
year following epilepsy diagnosis if it was not recorded in the patient’s medical 
record. 
Inpatient and emergency hospital care: Read codes for hospital admissions were 
categorised into inpatient admissions which included elective or planned patient 
admission and non-elective admission  (unplanned admission). Emergency hospital 
care also included the non-admitted accident and emergency (A&E) department 
visits. This classification was based on the 2011 Department of Health- reference 
costs guideline (Department of Health, 2011). 
Diagnostic imaging: Read codes for diagnostic imaging were extracted and 
principally included electroencephalogram (EEG), computerised tomography (CT) 
and magnetic resonance imaging (MRI). Read codes referring to EEG details such as 
prolonged ambulatory or video telemetry EEG were not identified. Therefore the unit 
cost of routine EEG were attached to the calculated cost data.  
Blood chemistry tests: Codes for relevant biochemistry tests for monitoring blood 
levels of AEDs were used to identify monitoring activity.  
Prescribed medications for epilepsy: All prescriptions for older (approved before 
1990) and newer (approved after 1990) AEDs were identified and extracted from 
CYP’s therapy records using the British National Formulary for children (BNF 
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2011) codes for AEDs. The data included information on the quantity prescribed, 
formulation and dosage strength. 
Cost information and assigning costs to heath resource use 
To assign costs to each element of HRU we used the most up-to-date Department of 
Health Reference Costs at the time of our study (Department of Health, 2011), the 
Personal Social Services Research Unit (PSSRU) Costs of Health and Social Care 
(Curtis 2011), the BNF for children (BNF 2011) and the NHS Electronic Drug Tariff 
2011(NHS Electronic Drug Tariff, 2011) which are summarised in Table 1 to show 
the unit cost of each element of HRU.  
The unit cost of a GP consultation was obtained using the average unit cost per a GP 
visit lasting 11.7 minutes without qualifications and including direct care staff costs. 
The costs of AEDs were calculated for each prescription by multiplying the price 
guidance obtained from the BNF for children 2011 for each drug formulation by the 
quantity prescribed. For example, if a child was prescribed 600 ml of sodium 
valproate liquid and the unit price in the BNF was £6.13 for 300ml-pack, the cost of 
this prescription was calculated as 2x £6.13=£12.26. Formulations for clobazam, 
clonazepam, midazolam and paraldehyde (which accounted for 1% of all 
prescriptions) are extemporaneous preparations and are usually provided by special 
orders. The costs of these formulations were obtained from the NHS Electronic Drug 
Tariff 2011.  
2.4. Statistical analyses of health resource use and associated costs 
For each element of HRU, we calculated the annual mean utilisation per CYP with 
epilepsy for each year following diagnosis. We also calculated the mean direct costs 
of each HRU element per child per year, starting from the date of diagnosis, by 
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multiplying the number of units of each element per year by the fixed unit cost 
values. We calculated the arithmetic mean of the cost of each element as this 
provides information about the total costs required to treat all patients and so is 
considered the most useful measure for health care policy decisions (Briggs and 
Gray 1998). We similarly calculated the arithmetic mean of the total cost of hospital 
care (comprised of inpatient and outpatient hospital care episodes, diagnostic 
imaging and blood chemistry tests), the total cost of AED prescriptions, and the 
overall total direct cost per child each year.  
Since cost data are typically right skewed due to a small number of high cost outliers 
in any patient cohort, nonparametric bootstrapping with replacement was adopted as 
the method to achieve an approximate normal distribution and to enable comparison 
of arithmetic means of the cost data (Briggs and Gray 1998). On the data generated 
by bootstrapping, unpaired t-tests were used to compare the annual total costs 
between males and females. Analysis of variance was used to compare the annual 
costs between age groups and quintiles of the Townsend index. Cost estimates were 
calculated in UK pound sterling (GBP) and converted to US dollars and Euros using 
the exchange rates on December 31st, 2011. All analyses were carried out using 
STATA V.11 (StataCorp, College Station, Texas, USA).  
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3. Results  
3.1. Study population  
From the initial study population of 528,760 CYP, 2020 (0.4%) had epilepsy 
according to our definition and 798 of these were newly diagnosed incident cases 
during the study period who also had at least one year of data following diagnosis 
(mean 6 years of follow up, Standard Deviation (SD) 3.6). Seventy percent (560) of 
the incident cases had their registration date at or within 6 months of their date of 
birth. Of the incident cases, 444 (56%) were male and the age at diagnosis ranged 
from 1 day to 15.5 years (mean age was 5.6 years; SD=3.8).  
3.2. Health resource utilisation and associated costs 
The HRU each year following epilepsy diagnosis is described in Table 2. Apart from 
A&E visits and AED prescriptions, the mean number of annual GP consultations, 
outpatient attendances, inpatient admissions, diagnostic imaging and blood chemistry 
tests per CYP were all highest in the first year following diagnosis. The mean number 
of AED prescriptions per CYP remained almost unchanged over the years following 
diagnosis. Inpatient admissions, A&E visits and diagnostic imaging occurred less than 
yearly for the majority of patients, over most years of follow-up. Of diagnostic tools, 
EEG were more likely used than MRI and CT scans. 
The direct medical costs of HRU each year following epilepsy diagnosis are shown in 
Table 3. The mean total direct cost per CYP was £930 (95% CI £839-1,022) in the 
first year following diagnosis and ranged from £368 (95% CI £264-473) to £587 
(95% CI £300-873) in consecutive follow-up years. Each year, small proportions (4-
11%) of CYP had a high total direct cost of more than £2000.  
For every year, hospital care costs comprised the largest contribution to the total 
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direct cost per child followed by the cost of AED prescriptions (Figure 1). In the first 
year, hospital care costs accounted for 80% of the total direct medical costs and then 
ranged from 45% to 67% in consecutive years, inpatient admissions accounted for 
most of these (33% to 59% of the total direct costs). Over the years of follow-up, 
AED prescriptions accounted for 13% to 50% and GP consultations accounted for 4% 
to 8% of the total direct medical costs.   
The annual costs of AEDs per child increased from £118 (95% CI £100-137) in the 
first year to £208 (95% CI £160-257) in the eighth year following diagnosis with 
newer AEDs accounting for a larger proportion of the costs over time (Table 3 and 
Figure 2).  
Table 4 shows the variation of the annual medical costs of HRU by sociodemographic 
factors of CYP. The mean total medical costs per child were higher for males 
compared with females, but this was only statistically significant in the first year 
following diagnosis when costs in females were 80% of the mean cost in males (£808 
versus £1,027 in males; t-test on bootstrapped data, p values for each year are shown 
in Table 4). The study cohort included only four patients with age at diagnosis in the 
neonatal period (up to 28 days). Therefore, the cost of neonatal epilepsy management 
was calculated and added to that of the age range of infancy. The mean total direct 
medical costs per child were higher in younger age groups than in older age groups, 
which remained over the 4 years following diagnosis. (ANOVA test, p-values for 
each year are shown in Table 4).  The total medical costs did not vary by Townsend 
deprivation quintiles (ANOVA test, p values for each year are shown in Table 4).
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4. Discussion  
We have shown that the HRU and direct medical costs of CYP newly diagnosed with 
epilepsy are high although there are variations based on the investigations required, 
hospital care and AED treatment plan. Costs are highest in the first year following 
diagnosis but subsequent annual costs remain stable, without decreases, regardless of 
the age at diagnosis. Annual costs are spread across most elements of HRU, 
particularly with primary care consultations, inpatient and outpatient hospital care, 
and AED prescriptions remaining consistent in the years following diagnosis. Costs of 
HRU were lower in girls compared with boys by a modest amount, although in the 
first year following diagnosis costs in girls were only 80% of those in boys. Annual 
direct medical costs decreased with increasing age, however, there were no 
differences by socioeconomic deprivation indicating similar consultation and care 
across these groups. 
Variation in HRU and associated medical costs among CYP likely reflects the 
heterogenic nature of epilepsy in terms of diagnosis, seizure severity and response to 
treatment. For example, some CYP with uncontrolled (drug-resistant) seizures may 
lead to more hospital care services and/or higher AED costs. Unfortunately, it was not 
possible to assess HRU by diagnostic subtypes of epilepsy or by seizure severity 
because these data were not recorded with adequate specificity for the majority of our 
cohort in their general practice records. A previous survey study investigated the 
association between the cost and severity of seizures in 696 adults and 93 CYP 
under16 years (Jacoby et al., 1998) and reported that patients with more frequent 
seizures consumed more than one-half of total combined costs of direct and indirect 
care for epilepsy. The annual total direct health care cost (adult and children 
combined) was £689 per patient, ranging from £162 for patients with no seizures to 
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£1525 for those with >1 seizure per month.  
Apart from initial paediatric neurologist consultations, which should form part of the 
diagnostic process, the highest contribution to the annual direct medical costs of 
epilepsy was that of inpatient hospital admissions followed by AED prescriptions. 
This contribution of HRU elements to total direct medical costs is consistent with that 
found in Cockrell et al’s study, a prospectively followed cohort of 602 patients of all 
ages (25% of whom were under age 15 years) identified from general practices 
throughout the UK (Cockerell et al., 1994). Similar to our findings, the authors 
calculated higher total costs in the first year of follow-up (£611) than in successive 
years (e.g. £ 169 in the 8th year). The authors did not provide separate cost data for 
epilepsy in children; only combined costing data for the adults and children were 
presented.  In another study, Jacoby et al estimated similar patterns of the contribution 
of HRU to the total direct costs to that of our study where the cost of inpatient 
hospital admissions was 58%, followed by AEDs (23%), outpatient attendances (7%) 
and GP consultations (2%) over a 12-month period (Jacoby et al., 1998). In contrast to 
our longitudinal study, their design was a cross-sectional survey estimating the costs 
of epilepsy for one year and included only 93 CYP less than 16 years old. Most 
information was based on patient questionnaires and GP medical records, which may 
have been subject to some inaccurate recall.  
The comparisons of our HRU and direct medical costs to that of CYP from different 
countries is difficult because of monetary differences and variation in policies for 
public and private health care systems. For example, an Italian study prospectively 
followed 189 CYP for 12 months and reported higher rates of hospitalisations and 
investigations than our study (Guerrini et al., 2001). The authors showed that the 
annual HRU such as investigations (e.g. mean EEG 1.8-3.5 per child) and hospital 
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admissions were higher in newly diagnosed CYP with epilepsy and those with drug-
resistant epilepsy. The annual cost per child was estimated at €1,635 which 
corresponds to £1,349, compared to our estimate of £930 in the first year following 
diagnosis. 
4.1. Medical costs and CYP’s sociodemographics 
The total direct costs per child were slightly higher in boys than in girls, although this 
was mostly in the first year following diagnosis. Although we were not able to assess 
clinical epilepsy subtype, this does not indicate that there are such substantial sex 
differences. The direct medical costs per child were significantly different across age 
groups of CYP and tended to be higher in younger age groups (<2 and 2-6 years) who 
comprised 65% of our cohort. Higher costs were attributed to more frequent 
hospitalisations and visits to the emergency departments.  This probably because the 
age of onset of some drug-resistant epilepsy subtypes (e.g. West syndrome and 
Dravet’s syndrome) which manifest more frequent seizures is at infancy and early 
childhood (Guerrini 2006). Very similar findings regarding age groups were reported 
when the costs of hospital care were estimated for 3,892 people (mostly adults) with 
epilepsy resident in Wales, UK (Morgan and Kerr 2004). A Canadian study of 1,431 
patients with epilepsy reporting health resource utilisation (HRU) over 1 year but not 
the associated costs, also suggested that CYP with epilepsy under 18 years of age 
were more likely than adults to see neurologists, visit emergency departments and be 
admitted to hospital (Jette et al., 2008). 
In our UK-wide study population, we did not find variation in total medical costs by 
socioeconomic deprivation, which indicates that the quality of care provided was the 
same for all CYP regardless of the area they lived in. A previous study reported a 
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weak correlation between deprivation and hospital care activity (r=0.59, (p<0.001) for 
inpatient admissions and for outpatient appointments: r=0.51 (p=0.001) among 2,028 
patients with epilepsy (Morgan et al., 2000). However, the data of this study were 
combined for adults and children and limited to hospital care utilisation in the health 
district of South Glamorgan, Wales, UK. The authors investigated prevalent cases of 
mostly adults with epilepsy (1996 estimate) which may have involved more 
medication non-adherence and/or severity of seizures.     
4.2. Strengths and limitations of the study 
This is one of few prospective studies estimating HRU and associated costs of 
epilepsy in a general population setting and, to our knowledge, the first to describe 
epilepsy only in CYP according to their sociodemographic variation. The study cohort 
was identified from a national population-based database, so the findings can be 
generalised to CYP with epilepsy in the UK. This study calculated the direct medical 
costs of CYP with epilepsy from initial diagnosis and over time and not only in the 
first year like some studies where the costs have been reported higher in the first year 
than for subsequent years. Our study provides new data to the scarcity of cost of 
illness studies in CYP with epilepsy.  As we were including only new cases of 
epilepsy, cases were required to have both a diagnosis and prescriptions for AEDs, a 
similar but slightly more specific definition than that used by Meeraus et al (Meeraus 
et al., 2013) also using the THIN general practice database.  There are no standard 
ways to identify clinical epilepsy using routine health data and no specific studies that 
have assessed their sensitivity and specificity in children, however, we assessed the 
external validity of our definition by comparing our cohort’s incidence and prevalence 
(Ali 2012) to that of a UK Clinical Practice Research Datalink study for the same age 
range of children (Wallace et al., 1998).  
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A number of limitations have been encountered in this study. First because of routine 
data may not identify all health resources required, assumptions have been made to 
correct for the lower recoding of neurologist outpatient appointments. For example, 
the cost of one paediatric neurology visit per child was added in the first year; this 
was considered reasonable based on the recommendations of NICE Guideline 2004 
for diagnosis and management of epilepsy in CYP (Stokes et al., 2004), although the 
actual neurologist consultations may have been underestimated for subsequent years 
following diagnosis. Furthermore, the costs of hospital care were estimated from the 
mean costs per episode as it was not possible to distinguish between epilepsy-related 
and non-epilepsy related hospital care in THIN.  Morgan et al’s previous study, 
however, indicated that differentials between patients with and without epilepsy were 
very high for CYP compared with adults (Morgan and Kerr 2004). 
Despite these limitations, this study indicates that epilepsy represents a significant 
economic burden to the health care provider. This study provides baseline data for 
further economic evaluations on the burden of epilepsy in CYP. Prospective data 
collection on the specialists’ appointments and hospital care may be required for 
future analysis of the direct medical costs of treating epilepsy.  
5. Conclusions 
The mean direct medical costs of managing epilepsy in CYP were higher in the first 
year of diagnosis than the consecutive years due to diagnostic process. The largest 
element of HRU contributed to the total direct medical costs of epilepsy was inpatient 
hospital care, followed by the costs of AEDs. Direct medical costs significantly 
decreased with age, but were similar between boys and girls and across 
socioeconomic groups.  
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Table 1: Unit cost of health care resources 
Health care resource  Unit   Unit 
Cost (£) 
 Source  
GP consultation 1  30 PSSRU 2011 
Hospital care episodes  
Paediatric neurology outpatient attendances 
Other outpatient attendances  
Elective inpatient admissions 
Non-elective inpatient admissions (e.g.   
emergency admission) 
A&E visits (with no inpatient stay) 
 
1              
1 
1 
1 
 
1 
 
354 
101 
3091 
568 
 
108 
 
DH Reference Costs 2011 
DH Reference Costs 2011 
DH Reference Costs 2011 
DH Reference Costs 2011 
 
DH Reference Costs 2011 
Diagnostic imaging  
CT 
EEG 
MRI  
 
1 
1 
1 
 
95 
93 
163 
 
DH Reference Costs 2011 
DH Reference Costs 2011 
DH Reference Costs 2011  
Blood chemistry tests  1 1 DH Reference Costs 2011  
Older AEDs 
Carbamazepine, clobazam, ethosuximide, 
phenobarbital, phenytoin, primidone and sodium 
valproate preparations 
 
 
 
 
 
 
 
BNF for children 2011 
 
Clobazam suspension 5mg/5ml  
Clonazepam oral drops 2.5 mg/ml 
Clonazepam suspension 500µg /5ml 
Midazolam buccal solution 10mg/ml 
Paraldehyde injection  
100 ml 
20 ml 
100 ml 
25 ml 
10ml 
 NHS Electronic Drug Tariff 
 
Newer AEDs 
Lamotrigine, Levetiracetam, topiramate, 
gabapentin, oxcarbazepine, tiagabine and 
vigabatrin preparations  
 
 
 
 
 
BNF for children 2011 
 
AEDs: antiepileptic drugs; A&E: accident and emergency; BNF: British National Formulary; 
CT: computerised tomography; DH: Department of Health; GP: general practitioner; EEG: 
electroencephalogram; MRI: magnetic resonance imaging; NHS: National Health Service; 
PSSRU: Personal Social Services Research Unit
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Table 2: Mean health resource utilisation per child for CYP with epilepsy  
Years after 
epilepsy 
diagnosis  
Number 
of CYP  
GP consultations 
(SD) 
 Hospital care episodes (SD) 
 
Diagnostic  imaging (SD) Blood  
chemistry 
tests 
Prescriptions of 
AEDs (SD) 
Outpatient Inpatient A&E CT EEG MRI  
1st  798 2.28  
(2.48) 
0.34  
(1.18) 
0.10  
(0.39) 
0.09 
(0.86) 
0.03 
(0.14) 
0.12 
(0.38) 
0.08 
(0.32) 
0.05  
(0.27) 
11.40 
(8.46) 
2nd  754 0.94 
(1.53) 
0.25 
(0.93) 
0.07 
(0.40) 
0.08 
(0.64) 
0.01 
(0.03) 
0.03 
(0.18) 
0.03 
(0.20) 
0.04 
(0.33) 
12.45 
(9.57) 
3rd  653 0.83 
(1.42) 
0.18 
(0.76) 
0.08 
(0.48) 
0.09 
(0.45) 
0.01 
(0.04) 
0.04 
(0.22) 
0.01 
(0.12) 
0.03 
(0.20) 
12.03 
(10.31) 
4th  530 0.77 
(1.37) 
0.23 
(0.92) 
0.06 
(0.46) 
0.05 
(0.34) 
0.01 
(0.06) 
0.04 
(0.19) 
0.04 
(0.30) 
0.04 
(0.21) 
12.18 
(11.02) 
5th  400 0.73 
(1.07) 
0.21 
(0.73) 
0.11 
(0.92) 
0.09 
(0.41) 
0.01 
(0.05) 
0.04 
(0.20) 
0.02 
(0.14) 
0.02 
(0.19) 
12.29 
(11.20) 
6th  319 0.64 
(1.13) 
0.13 
(0.58) 
0.05 
(0.28) 
0.09 
(0.43) 
0.00 
(0) 
0.02 
(0.16) 
0.03 
(0.20) 
0.03 
(0.18) 
12.06 
(12.55) 
7th  223 0.65 
(1.40) 
0.19 
(0.68) 
0.05 
(0.35) 
0.15 
(0.79) 
0.00 
(0) 
0.05 
(0.25) 
0.04 
(0.17) 
0.01 
(0.16) 
12.05 
(12.24) 
8th  175 0.78 
(1.60) 
0.15 
(0.50) 
0.05 
(0.24) 
0.13 
(0.53) 
0.00 
(0) 
0.03 
(0.13) 
0.03 
(0.17) 
0.03 
(0.21) 
12.00 
(12.63) 
AEDs: antiepileptic drugs; A&E: accident and emergency; CT: computerised tomography; CYP: children and young people; GP: general practitioner; EEG: 
electroencephalogram; MRI: magnetic resonance imaging; SD: standard deviation. 
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Table 3: Mean direct medical costs per child for CYP with epilepsy  
Years after epilepsy diagnosis (number of CYP) 
 Cost category  1st  (n =798) 2nd  (n=754) 3rd (n=653) 4th (n=530) 5th (n=400) 6th (n=319) 7th (n=223) 8th (n=175) 
 Mean cost per child* (95% confidence interval)  
GP consultations 73 (68-78) 28 (25-31) 24 (21-28) 22 (19-26) 21 (18-24) 18 (14-22) 17 (12-23) 21 (14-18) 
Hospital care episodes 
 Outpatient 
  Paediatric neurology  
  Other outpatient 
Inpatient admissions 
A&E visits 
 
 
354 (0) 
34 (26-42) 
306 (223-390) 
19 (10-28) 
 
 
0 
25 (19-32) 
230 (19-32) 
11 (4-17) 
 
 
0 
17 (11-23) 
241 (126-351) 
17 (9-26) 
 
 
0 
23 (16-31) 
187 (65-308) 
11 (4-17) 
 
 
0 
21 (14-28) 
349 (68-629) 
13 (7-23) 
 
 
0 
13 (7-20) 
136 (51-239) 
13 (6-21) 
 
 
0 
19 (10-28) 
166 (23-310) 
20 (5-34) 
 
 
0 
16 (8-23) 
141 (33-250) 
18 (5-32) 
Diagnostic imaging  
CT 
EEG 
MRI  
 
2 (1-3) 
11 (9-14) 
12 (9-16) 
 
0 
3 (2-4) 
6 (3-8) 
 
0.2 (4) 
4 (2-5) 
2 (0.5-4) 
 
0.4 (0.1-0.9) 
3 (2-5) 
7 (3-11) 
 
0.5 (0.2-0.7) 
4 (2-6) 
3 (0.2-5) 
 
0 
2 (0.1-3) 
5 (1-8) 
 
0 
4 (1-7) 
5 (1-9) 
 
0 
2 (1-3) 
5 (1-9) 
Blood chemistry tests 0.1 (0.3) 0.1 (0.3)  0.1 (0.2) 0.1 (0.2) 0.1(0.2) 0.1 (0.2) 0.1(0.1) 0.1 (0.2) 
AEDs 
Old AEDs 
New AEDs  
 
94 (77-112) 
24 (18-30) 
 
108 (96-120) 
50 (40-59) 
 
110 (90-129) 
61 (49-73) 
 
107 (90-124) 
70 (56-84) 
 
102 (85-120) 
71 (53-88) 
 
93 (75-110) 
82 (59-104) 
 
87 (74-100) 
108 (74-142) 
 
92 (74-110) 
117(72-161) 
Total cost of hospital 
care per child 
739 (651-827) 
 
276 (186-365) 
 
281 (166-397) 
 
232 (107-357) 
 
393 (112-675) 
 
177 (79-275) 217 (70-365) 
 
184 (71-296) 
Total cost of AEDs per 
child 
118 (100-137) 157 (141-174) 170 (147-193) 177 (154-200) 173 (148-198) 174 (146-203) 194 (159-230) 208 (160-257) 
Total direct medical cost 
per child 
£930 (839-1022) 
$1437 (1297-1580) 
€1110 (1001-1220) 
£461 (368-551) 
$713 (569 852) 
€550 (439-658) 
£475 (353-591) 
$734 (546-913) 
€567 (421-705) 
£430 (300-561) 
$665 (464-867) 
€513 (358-670) 
£587(300-873) 
$907 (464-1349) 
€701 (358-1042) 
£368 (264-473) 
$569 (408-731) 
€439 (315-565) 
£429 (273-579) 
$663 (422-895) 
€512 (326-691) 
£413 (282-540) 
$638 (436-835) 
€493 (337-644) 
*All estimated costs per year were rounded to nearest whole UK£ unless otherwise indicated. Total direct medical costs are also calculated in US$ and Euro €. 
AEDs: antiepileptic drugs; A&E: accident and emergency; CT: computerised tomography; CYP: children and young people; GP: general practitioner; EEG: 
electroencephalogram; MRI: magnetic resonance imaging.     
 
       22 
Table 4: Mean annual total direct medical costs per child according to sociodemographic factors of CYP with epilepsy 
 Years after epilepsy diagnosis (number of CYP) 
Factors  1st year (n=798)  2nd year (n=754) 3rd year (n=653) 4th year (n=530) 
Number 
of CYP  
Mean cost* 
(95% CI)a 
Number 
of CYP 
Mean cost* 
(95% CI)a 
Number 
of CYP   
Mean cost* 
(95% CI)a 
Number 
of CYP  
Mean cost* 
(95% CI)a 
Sex             
Male   444  £1027 (940-1186) 
$1587 (1453-1833) 
€1226 (1122-1416) 
 
0.04b 
420  £507 (399-712) 
$784 (617-1100) 
€605 (476-850) 
 
0.36b 
363  £521(375-794) 
$805 (580-1227) 
€622 (448-948) 
 
0.64b 
 
292  £440 (329-766) 
$680 (509-1184) 
€525 (393-914) 
 
0.18b 
 
Female  354  £808 (718-935) 
$1249 (1110-1445) 
€964 (857-1116) 
334  £395 (324-528) 
$611 (501-816) 
€471 (387-630) 
290 £415 (324-567) 
$641 (501-876) 
€495 (387-677) 
238  £414 (295-721) 
$640 (456-1114) 
€494 (352-861) 
Age (years, time-
varying) 
            
< 2  192 £1203 (992-1447) 
$1859 (1533-2236) 
€1436 (1184-1727) 
 
0.01c 
102 £1007(619-1705) 
$1556 (957-2635) 
€1202 (739-2035) 
 
0.01c 
0 -  
 
 
 
0.02c 
0 -  
 
 
 
0.05c 
2-6 255  £921 (784-1112) 
$1423 (1212-1719) 
€1099 (936-1327) 
248  £478 (371-659) 
$739 (573-1019) 
€570 (443-787) 
259 £743 (508-1083) 
$1148 (785-1674) 
€887 (606-1293) 
175  £697 (428-1173) 
$1077 (662-1813) 
€832 (511-1400) 
7-12 303  £810 (706-954) 
$1252 (1091-1475) 
€967 (843-1139) 
321 £296 (236-383) 
$457 (365-592) 
€353 (282-457) 
306 £306 (244-407) 
$473 (377-629) 
€365 (291-486) 
264  £318 (236-449) 
$492 (365-694) 
€380 (282-536) 
>12 48  £655 (600-731) 
£1012 (927-1130) 
€782 (716-872) 
83   £290 (179-438) 
448 (277-677) 
€346 (214-523) 
88  £270 (170-373) 
$417 (263-577) 
€322 (203-445) 
91 £233 (144-382) 
$360 (223-590) 
€278 (172-456) 
*All estimated costs per year were rounded to nearest whole UK£, US$ and Euro €  
a: bootstrapped bias corrected and accelerated confidence intervals         b: t-test p-value on bootstrapped data            c: One way ANOVA p value on bootstrapped data 
All estimated costs were rounded to nearest whole UK£.  CI: confidence interval; CYP: children and young people.  
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    Table 5: continued 
Factors  1st year (n=798)  2nd year (n=754) 3rd year (n=653) 4th year (n=530) 
Number 
of CYP 
Mean cost* 
(95% CI)a 
Number 
of CYP 
Mean cost* 
(95% CI)a 
Number 
of CYP 
Mean cost* 
(95% CI)a 
Number 
of CYP  
Mean cost* 
(95% CI)a 
Townsend quintile             
1 (least deprived) 147 £813 (673-1026) 
$1257 (1040-1586) 
€970 (803-1225) 
 
0.67c 
143  £379 (275-513) 
$586 (425-793) 
€452 (328-612) 
 
0.29c 
119 £329 (215-503) 
$509 (332-777) 
€393 (257-600) 
 
0.71c 
91  £376 (234-571) 
$581 (362-883) 
€449 (279-681) 
 
0.93c 
2 123  £1095 (837-1445) 
$1692 (1294-2233) 
€1307 (999-1725) 
113  £577 (352-911) 
$892 (544-1408) 
€689 (420-1087) 
102 £397 (233-645) 
$614 (360-997) 
€474 (278-770) 
82  £275 (195-415) 
$425 (301-641) 
€328 (233-495) 
3 168 920 (759-1120) 
$1422 (1173-1731) 
€1098 (906-1337) 
157  £419 (303-619) 
$648 (468-957) 
€500 (362-739) 
133 £411 (256-585) 
$635 (396-904) 
€491 (306-698) 
113  £518 (290-945) 
$801 (448-1461) 
€618 (346-1128) 
4 170  998 (811-1233) 
$1543 (1253-1906) 
€1191 (968-1472) 
159  £477 (338-686) 
$737 (522-1060) 
€569 (403-819) 
143 £608 (394-1030) 
$940 (609-1592) 
€726 (470-1229) 
115  £407 (265-688) 
$629 (410-1063) 
€486 (316-821) 
5 (most deprived) 135  851 (692-1072) 
$1315 (1070-1657) 
€1016 (826-1279) 
129  £405 (255-562) 
$626 (394-869) 
€483 (304-671) 
111 £486 (293-708) 
$751 (453-1094) 
€580 (350-845) 
93  £299 (190-448) 
$462 (294-692) 
€357 (227-535) 
Missing  55  £891 (605-1415) 
$1377 (935-2187) 
€1063 (722-1689) 
53  £615 (169-1869) 
$951(261-2889) 
€734 (202-2231) 
45 £808 (203-2400) 
$1249 (314-3709) 
€964 (242-2864) 
36  £1030 (239-3070) 
$1592 (369-4745) 
€1229 (285-3664) 
 
*All estimated costs per year were rounded to nearest whole UK£, US$ and Euro €  
a: bootstrapped bias corrected and accelerated confidence intervals         b: t-test p-value on bootstrapped data            c: One way ANOVA p value on bootstrapped data 
All estimated costs were rounded to nearest whole UK£.  CI: confidence interval; CYP: children and young people. 
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Figure 1: Total annual direct medical costs per child for CYP with epilepsy  
 
Figure 2: Total annual costs of old and new AEDs for CYP with epilepsy 
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